AMWL — American Well Corporation

Summary of American Well Corporation (AMWL) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $249.3 million for FY 2025, with Q4 revenue at $55.3 million, a 22.1% year-over-year decline.
• Subscription Revenue: Represented 53% of total revenue, up from 45% in 2024; Q4 subscription revenue was $28.8 million, down 22% year-over-year.
• Adjusted EBITDA: Q4 loss of $10.3 million, improved from a loss of $12.7 million in Q3 2025 and $22.8 million in Q4 2024.
• Net Loss: $25.2 million in Q4, down from $30.7 million in Q3 2025.
• Cash Position: Ended 2025 with approximately $182 million in cash and marketable securities, no debt.
• Cash Burn: Approximately $19 million in Q4.

2. Strategic Updates and Business Highlights

• Transformation Focus: Shifted to a technology-enabled care platform, divesting non-core activities and reducing costs significantly.
• Market Positioning: Emphasized the need for operational efficiency in healthcare, with a focus on AI integration to enhance patient engagement and care delivery.
• Contract Renewals: Secured over 15 payer contract renewals, including a significant three-year renewal with Elevance.
• Operational Efficiency: Reduced operating expenses by 30.7% year-over-year in Q4, improving operating expenses as a percentage of revenue to 96.7%.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $195 million and $205 million.
• Visit Volume: Anticipated AMG visits between 1.32 million and 1.37 million.
• Adjusted EBITDA Loss: Projected to be between $24 million and $18 million for FY 2026, with Q1 guidance for revenue between $48 million and $53 million.
• Cash Flow Breakeven: Aiming for positive cash flow from operations by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Notable decline in total revenue and subscription revenue primarily due to the step down in the DHA contract and churn from previous years.
• Visit Volume Decrease: Total platform visits fell to 1 million, down 28.4% year-over-year.
• Competitive Pressures: Increasing competition from new AI companies in the healthcare space, necessitating a robust strategy to maintain market position.
• Contract Renewals: The upcoming DHA renewal in summer 2026 poses a risk, although management is optimistic about securing a longer-term contract.

5. Notable Q&A Insights

• Client Contracts: Most renewals in 2026 are expected to be lower, with the exception of the DHA renewal, which is crucial for maintaining revenue stability.
• AI Integration: Management expressed optimism about AI's role in enhancing healthcare delivery but acknowledged the challenges of integrating multiple AI programs into existing infrastructures.
• Market Opportunities: A robust pipeline of government contracts is anticipated, with potential revenue not yet included in the 2026 guidance.
• Long-Term Growth: Emphasis on same-store growth and the ability to leverage existing relationships for new opportunities, particularly in the payer and government sectors.

Overall, American Well Corporation is navigating a transformative phase, focusing on operational efficiency and AI integration while managing challenges related to revenue decline and competitive pressures. The company aims for a stronger financial position in 2026 with a clear path to cash flow breakeven.